Free Trial
→ The one number Musk can't hide in the S-1 (From Behind the Markets) (Ad)tc pixel
NASDAQ:CDT

CDT Equity 3/28/2025 Earnings Report

CDT Equity logo
$2.12 +0.23 (+12.17%)
Closing price 05/13/2026 03:59 PM Eastern
Extended Trading
$2.14 +0.02 (+1.18%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

CDT Equity EPS Results

Actual EPS
-$60,990.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CDT Equity Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CDT Equity Announcement Details

Quarter
Date
3/28/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

CDT Equity Earnings Headlines

CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290008/0/en/cdt-notes-sarborg-filing-of-substance-of-matter-patent-in-cystic-fibrosis-market.html
Analyzing Fractyl Health (NASDAQ:GUTS) & CDT Equity (NASDAQ:CDT)
May 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30764400
The one number Musk can't hide in the S-1
When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requires more electricity than some small countries use in a year, and SEC rules require it be disclosed. When that figure goes public, every analyst on Wall Street will race to identify the supplier. One small company already has a $1.5 billion backlog - and Dylan Jovine has the name and ticker.tc pixel
 |  Behind the Markets (Ad)
CDT Equity (NASDAQ:CDT) Trading 8.7% Higher - Here's Why
May 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30763192
CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288812/0/en/cdt-advances-azd5904-into-global-patent-phase-and-initiates-partnering-discussions.html
CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
April 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/16/3275336/0/en/cdt-expands-multi-pathway-value-creation-strategy-across-pharma-ip-and-ai-driven-discovery.html
See More CDT Equity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CDT Equity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CDT Equity and other key companies, straight to your email.

About CDT Equity

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

View CDT Equity Profile
Earnings Tools